213 related articles for article (PubMed ID: 12176892)
21. Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia.
Mohan SR; Clemente MJ; Afable M; Cazzolli HN; Bejanyan N; Wlodarski MW; Lichtin AE; Maciejewski JP
Haematologica; 2009 Oct; 94(10):1407-14. PubMed ID: 19794084
[TBL] [Abstract][Full Text] [Related]
22. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
Zhang Z; Zhang M; Goldman CK; Ravetch JV; Waldmann TA
Cancer Res; 2003 Oct; 63(19):6453-7. PubMed ID: 14559836
[TBL] [Abstract][Full Text] [Related]
23. Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.
Chakraverty R; Orti G; Roughton M; Shen J; Fielding A; Kottaridis P; Milligan D; Collin M; Crawley C; Johnson P; Clark A; Parker A; Bloor A; Pettengell R; Snowden J; Pettitt A; Clark R; Hale G; Peggs K; Thomson K; Morris E; Mackinnon S
Blood; 2010 Oct; 116(16):3080-8. PubMed ID: 20587785
[TBL] [Abstract][Full Text] [Related]
24. Myeloid blood CD11c(+) dendritic cells and monocyte-derived dendritic cells differ in their ability to stimulate T lymphocytes.
Osugi Y; Vuckovic S; Hart DN
Blood; 2002 Oct; 100(8):2858-66. PubMed ID: 12351396
[TBL] [Abstract][Full Text] [Related]
25. 1-alpha,25-Dihydroxyvitamin D3 (1,25(OH)(2)D(3)) hampers the maturation of fully active immature dendritic cells from monocytes.
Canning MO; Grotenhuis K; de Wit H; Ruwhof C; Drexhage HA
Eur J Endocrinol; 2001 Sep; 145(3):351-7. PubMed ID: 11517017
[TBL] [Abstract][Full Text] [Related]
26. CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab.
Osuji N; Del Giudice I; Matutes E; Morilla A; Owusu-Ankomah K; Morilla R; Dunlop A; Catovksy D
Leuk Lymphoma; 2005 May; 46(5):723-7. PubMed ID: 16019510
[TBL] [Abstract][Full Text] [Related]
27. A novel approach to induce human DCs from monocytes by triggering 4-1BBL reverse signaling.
Ju S; Ju S; Ge Y; Qiu H; Lu B; Qiu Y; Fu J; Liu G; Wang Q; Hu Y; Shu Y; Zhang X
Int Immunol; 2009 Oct; 21(10):1135-44. PubMed ID: 19684160
[TBL] [Abstract][Full Text] [Related]
28. Acute cellular rejection predominated by monocytes is a severe form of rejection in human renal recipients with or without Campath-1H (alemtuzumab) induction therapy.
Zhang PL; Malek SK; Prichard JW; Lin F; Yahya TM; Schwartzman MS; Latsha RP; Norfolk ER; Blasick TM; Lun M; Brown RE; Hartle JE; Potdar S
Am J Transplant; 2005 Mar; 5(3):604-7. PubMed ID: 15707416
[TBL] [Abstract][Full Text] [Related]
29. Characterization of canine monocyte-derived dendritic cells with phenotypic and functional differentiation.
Wang YS; Chi KH; Liao KW; Liu CC; Cheng CL; Lin YC; Cheng CH; Chu RM
Can J Vet Res; 2007 Jul; 71(3):165-74. PubMed ID: 17695590
[TBL] [Abstract][Full Text] [Related]
30. Recognition of CD52 allelic gene products by CAMPATH-1H antibodies.
Hale C; Bartholomew M; Taylor V; Stables J; Topley P; Tite J
Immunology; 1996 Jun; 88(2):183-90. PubMed ID: 8690449
[TBL] [Abstract][Full Text] [Related]
31. Anti-CD52 antibody-mediated immune ablation with autologous immune recovery for the treatment of refractory juvenile polymyositis.
Reiff A; Shaham B; Weinberg KI; Crooks GM; Parkman R
J Clin Immunol; 2011 Aug; 31(4):615-22. PubMed ID: 21541793
[TBL] [Abstract][Full Text] [Related]
32. Activity of alemtuzumab in patients with CD52-positive acute leukemia.
Tibes R; Keating MJ; Ferrajoli A; Wierda W; Ravandi F; Garcia-Manero G; O'Brien S; Cortes J; Verstovsek S; Browning ML; Faderl S
Cancer; 2006 Jun; 106(12):2645-51. PubMed ID: 16688777
[TBL] [Abstract][Full Text] [Related]
33. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
von Kutzleben S; Pryce G; Giovannoni G; Baker D
Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
[TBL] [Abstract][Full Text] [Related]
34. Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52).
Osterborg A; Werner A; Halapi E; Lundin J; Harmenberg U; Wigzell H; Mellstedt H
Eur J Haematol; 1997 Jan; 58(1):5-13. PubMed ID: 9020367
[TBL] [Abstract][Full Text] [Related]
35. Costimulatory function of umbilical cord blood CD14+ and CD34+ derived dendritic cells.
Dilioglou S; Cruse JM; Lewis RE
Exp Mol Pathol; 2003 Aug; 75(1):18-33. PubMed ID: 12834622
[TBL] [Abstract][Full Text] [Related]
36. The CD45 tyrosine phosphatase regulates Campath-1H (CD52)-induced TCR-dependent signal transduction in human T cells.
Hederer RA; Guntermann C; Miller N; Nagy P; Szollosi J; Damjanovich S; Hale G; Alexander DR
Int Immunol; 2000 Apr; 12(4):505-16. PubMed ID: 10744652
[TBL] [Abstract][Full Text] [Related]
37. Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis.
Rao SP; Sancho J; Campos-Rivera J; Boutin PM; Severy PB; Weeden T; Shankara S; Roberts BL; Kaplan JM
PLoS One; 2012; 7(6):e39416. PubMed ID: 22761788
[TBL] [Abstract][Full Text] [Related]
38. CD52 expression in Waldenstrom's macroglobulinemia: implications for alemtuzumab therapy and response assessment.
Owen RG; Hillmen P; Rawstron AC
Clin Lymphoma; 2005 Mar; 5(4):278-81. PubMed ID: 15794865
[TBL] [Abstract][Full Text] [Related]
39. Interleukin-13 is involved in functional maturation of human peripheral blood monocyte-derived dendritic cells.
Sato K; Nagayama H; Tadokoro K; Juji T; Takahashi TA
Exp Hematol; 1999 Feb; 27(2):326-36. PubMed ID: 10029172
[TBL] [Abstract][Full Text] [Related]
40. Function of CD80 and CD86 on monocyte- and stem cell-derived dendritic cells.
Dilioglou S; Cruse JM; Lewis RE
Exp Mol Pathol; 2003 Dec; 75(3):217-27. PubMed ID: 14611813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
